Trillium Therapeutics
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Trillium Therapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 19% to $148,000. Profit margin reached -40099%. Total operating expenses were $61,603,000.

Profit Margin

Trillium Therapeutics Inc. (NASDAQ:TRIL): Profit margin
2011 0 -3.10M
2012 0 -1.06M
2013 0 -4.02M
2014 0 -11.09M
2015 0 -10.61M
2016 0 -23.60M
2017 0 -35.85M
2018 0 -31.19M
2019 124K -41.62M -33566.13%
2020 148K -59.34M -40098.65%

TRIL Income Statement (2011 – 2020)

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue
Revenue
148K124K00000000
Cost of revenue
147.85K000000000
Gross profit
148124K00000000
Operating exp.
Research and development
25.34M25.29M31.88M29.53M22.16M13.00M9.12M3.13M626.78K818.29K
Selling and marketing
0000000000
Total operating expenses
61.60M32.61M34.51M32.60M25.08M15.30M11.34M4.03M1.09M3.13M
Operating income
-61.45M-35.43M-34.51M-32.60M-25.08M-15.30M-11.34M-4.03M-1.09M-3.13M
Other income (expenses), net
2.21M-6.15M3.32M-3.25M-1.25M4.69M251.06K9.01K28.48K0
Income before tax
-59.24M-41.59M-31.18M-35.85M-26.34M-10.61M-11.09M-4.02M-1.06M0
Income tax expense
102K28K5.87K3.18K-2.73M6.84K311.16K46.70K00
Net income
-59.34M-41.62M-31.19M-35.85M-23.60M-10.61M-11.09M-4.02M-1.06M-3.10M
Earnings per share
Basic EPS
-0.71-1.65-2.24-3.67-3.02-1.6-2.64-2.97-18.09-5.87
Diluted EPS
-0.71-1.65-2.24-3.67-3.02-1.6-2.64-2.97-18.09-5.87
Data sourceData sourceData sourceData sourceData sourceData source